The Hawaii Headache & Facial Pain Center has been awarded Hawaii’s first research study investigating a potential preventive treatment for menstrual migraine in women using ubrogepant .
Migraine is one of the most common neurological conditions, especially among women. According to the American Migraine Foundation, two out of three women with migraine experience attacks that are linked to their menstrual cycle. These are known as menstrual migraines.
Understanding Menstrual Migraine
Menstrual migraines typically occur:
- Within two days before menstruation begins
- Up to three days after bleeding starts
These attacks are often:
- More intense
- Longer lasting
- More resistant to treatment
One of the primary contributors to menstrual migraine is the sharp drop in estrogen levels just before menstruation. This hormonal shift may affect brain chemicals involved in migraine, making these attacks particularly difficult to manage .
Investigating Ubrogepant for Preventive Treatment
Ubrogepant is an FDA-approved treatment for acute migraine. It is now being studied as a potential option for short-term prevention of menstrual migraine.
This Phase 3 clinical trial will enroll approximately 450 adult women across about 100 locations in the United States, including the Hawaii Headache & Facial Pain Center.
Participants will be:
- Randomly assigned to receive either ubrogepant or a placebo
- Taking the study medication during the high-risk days of their menstrual cycle
The goal of the study is to determine whether ubrogepant can reduce the frequency or severity of menstrual migraine attacks when taken preventively during this time .
Who May Qualify?
Women may qualify for the study if they:
- Have had migraine for at least one year
- Experience migraine attacks in at least 2 of 3 perimenstrual periods
- Have fewer than 15 headache days per month .
About the Study Design
This is a:
- Phase 3
- Multicenter
- Randomized
- Double-blind
- Placebo-controlled study
It will evaluate the efficacy, safety, and tolerability of ubrogepant for the preventive treatment of menstrual migraine, followed by an open-label extension phase .
Supporting Women’s Brain Health in Hawai‘i
“Our team of neurologists, neuroscience specialists and researchers in Hawaii are excited to take part in this clinical trial studying Ubrelvy for menstrual migraine. It’s an important step toward expanding treatment options for women who experience debilitating attacks around their menstruation, and we’re proud to support research that could truly make a difference.”
— Eonjung Angeline Kim, MD, Investigator & Director, Hawaii Headache & Facial Pain Center & Hawaii Headache Research Unit .
Learn More
For more information about the study, contact:
Hawaii Headache & Facial Pain Center
Hawaii Headache Research Unit
2230 Liliha Street #104
Honolulu, HI 96817
Research Hotline: (808) 564-6141
Email: info@infohawaiineuroscience-com.
